Zai Lab Limited - ZLAB
About Gravity Analytica
Recent News
- 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
- 09.04.2025 - Cantor Global Healthcare Conference
- 09.04.2025 - Cantor Global Healthcare Conference
- 09.03.2025 - Update on Amgen’s bemarituzumab Phase 3 FORTITUDE-101 Study
- 09.02.2025 - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
- 09.01.2025 - ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
- 09.01.2025 - Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
- 09.01.2025 - Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
- 09.01.2025 - Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
- 09.01.2025 - Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting